Cargando…

Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis

OBJECTIVE: Adamantinomas are rare low-grade malignant bone tumors. This study aims to describe the demographic characteristics and survival rates of patients suffering from adamantinomas. METHODS: The National Institute of Cancer Surveillance, Epidemiology, and Recent Results (SEER) database was use...

Descripción completa

Detalles Bibliográficos
Autores principales: Aytekin, Mahmut Nedim, Öztürk, Recep, Amer, Kamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315319/
https://www.ncbi.nlm.nih.gov/pubmed/32612653
http://dx.doi.org/10.1155/2020/2809647
_version_ 1783550233037242368
author Aytekin, Mahmut Nedim
Öztürk, Recep
Amer, Kamil
author_facet Aytekin, Mahmut Nedim
Öztürk, Recep
Amer, Kamil
author_sort Aytekin, Mahmut Nedim
collection PubMed
description OBJECTIVE: Adamantinomas are rare low-grade malignant bone tumors. This study aims to describe the demographic characteristics and survival rates of patients suffering from adamantinomas. METHODS: The National Institute of Cancer Surveillance, Epidemiology, and Recent Results (SEER) database was used, and patients diagnosed with adamantinoma between 1973 and 2016 were screened. Patients were classified according to sex, age, race/ethnicity, and marital status, and also tumors were classified according to year of diagnosis, laterality, type of treatment, and follow-up. RESULTS: The mean age of patients was 30.8 ± 16.7 (range: 4–75). A total of 92 patients were identified; of these, 43 were females and 49 were males. The mean follow-up period was 138.1 ± 90.3 (range: 1–156) months. Mean survival duration was 287.8 ± 15.4 (95% CI: 257.7–317.9) months. Five- and ten-year survival rates were 98.8% and 91.5%, respectively. Besides, survival time was also observed to be independent of gender, age groups, race, marital status, tumor location, and year of diagnosis. CONCLUSION: Adamantinoma is a very rare bone tumor that affects the long bones in lower extremities and is more common in men. Five- and 10-year survival prognoses are reasonably satisfactory. Also, survival time is independent of variables such as gender, age, and tumor location.
format Online
Article
Text
id pubmed-7315319
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73153192020-06-30 Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis Aytekin, Mahmut Nedim Öztürk, Recep Amer, Kamil J Oncol Research Article OBJECTIVE: Adamantinomas are rare low-grade malignant bone tumors. This study aims to describe the demographic characteristics and survival rates of patients suffering from adamantinomas. METHODS: The National Institute of Cancer Surveillance, Epidemiology, and Recent Results (SEER) database was used, and patients diagnosed with adamantinoma between 1973 and 2016 were screened. Patients were classified according to sex, age, race/ethnicity, and marital status, and also tumors were classified according to year of diagnosis, laterality, type of treatment, and follow-up. RESULTS: The mean age of patients was 30.8 ± 16.7 (range: 4–75). A total of 92 patients were identified; of these, 43 were females and 49 were males. The mean follow-up period was 138.1 ± 90.3 (range: 1–156) months. Mean survival duration was 287.8 ± 15.4 (95% CI: 257.7–317.9) months. Five- and ten-year survival rates were 98.8% and 91.5%, respectively. Besides, survival time was also observed to be independent of gender, age groups, race, marital status, tumor location, and year of diagnosis. CONCLUSION: Adamantinoma is a very rare bone tumor that affects the long bones in lower extremities and is more common in men. Five- and 10-year survival prognoses are reasonably satisfactory. Also, survival time is independent of variables such as gender, age, and tumor location. Hindawi 2020-06-16 /pmc/articles/PMC7315319/ /pubmed/32612653 http://dx.doi.org/10.1155/2020/2809647 Text en Copyright © 2020 Mahmut Nedim Aytekin et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Aytekin, Mahmut Nedim
Öztürk, Recep
Amer, Kamil
Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis
title Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis
title_full Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis
title_fullStr Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis
title_full_unstemmed Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis
title_short Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis
title_sort epidemiological study of adamantinoma from us surveillance, epidemiology, and end results program: iii retrospective analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315319/
https://www.ncbi.nlm.nih.gov/pubmed/32612653
http://dx.doi.org/10.1155/2020/2809647
work_keys_str_mv AT aytekinmahmutnedim epidemiologicalstudyofadamantinomafromussurveillanceepidemiologyandendresultsprogramiiiretrospectiveanalysis
AT ozturkrecep epidemiologicalstudyofadamantinomafromussurveillanceepidemiologyandendresultsprogramiiiretrospectiveanalysis
AT amerkamil epidemiologicalstudyofadamantinomafromussurveillanceepidemiologyandendresultsprogramiiiretrospectiveanalysis